Many pre-operative transgender women wait until after reassignment surgery to begin an active sex life. The sixth edition of the World Professional Association for Transgender Health 's Standards of Care permit it from Tanner stage 2 but do not allow the addition of hormones until age 16, which could be five or more years later. Handbook of Drug Interactions: Clinical evaluation and management". These changes may be reversed by surgery facial feminization surgery and tracheal shaverespectively.
Transsexual and Other Disorders of Gender Identity:
Transgender hormone therapy (male-to-female)
Breast development in trans women receiving cross-sex hormones". Additionally, AHI believes that our patients and clients do not need therapy to make a decision about whether hormone therapy is right for them. Mixed mechanism of action: Susceptibility to sunburn increases, possibly because the skin is thinner and less pigmented. Danazol Gestrinone Progestins e. On the fourth and fifth days a few drops of colostrum were expressed from the right nipple. Transgender women on HRT often experience less breast development than cisgender women especially if started after young adulthood.
Spironolactone is an antimineralocorticoid antagonist of the mineralocorticoid receptor and potassium-sparing diureticwhich is mainly used to treat high blood pressureedemahigh aldosterone levelsand low potassium levels caused by other diureticsamong other uses. This manifests most significantly as an increased risk for venous thromboembolism VTE: Mixed mechanism of action: Transgender hormone therapy of the male-to-female MTF type, also known as feminizing hormone therapyis hormone therapy and sex reassignment therapy to change the secondary sexual characteristics of transgender people from masculine or androgynous to feminine. Hinyokika Kiyo in Japanese. European Journal of Endocrinology. Wagner 27 November